Literature DB >> 8420374

Serum levels of interleukin-2 receptor in ocular Behçet's disease.

D BenEzra1, G Maftzir, I Kalichman, V Barak.   

Abstract

Serum interleukin-2 receptor levels were evaluated in 69 patients who had chronic bilateral uveitis and in 22 control subjects. Fifty-one of the 69 patients with uveitis had the ocular type of Behçet's disease and 18 had pars planitis (intermediate uveitis). The mean serum interleukin-2 receptor level was 412.6 +/- 94.6 U/ml for the control group, 465.0 +/- 96.6 U/ml for the patients with intermediate uveitis, and 810.9 +/- 369.3 U/ml for those with ocular Behçet's disease. The serum interleukin-2 receptor levels of patients with ocular Behçet's disease were significantly different from the levels of both the control and the intermediate uveitis groups (P < .001). The differences in serum levels of patients with intermediate uveitis and the levels of the control subjects were not statistically significant. Treatment of patients with ocular Behçet's disease for four to six weeks with either cyclosporine, methylprednisolone, or a combination of both, decreased the intraocular inflammation in nearly all cases. The influence of treatment on the level of serum interleukin-2 receptor, however, was variable.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8420374     DOI: 10.1016/s0002-9394(14)73520-2

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  7 in total

Review 1.  Cytokines and chemokines in uveitis: is there a correlation with clinical phenotype?

Authors:  Kenneth G-J Ooi; Grazyna Galatowicz; Virginia L Calder; Susan L Lightman
Journal:  Clin Med Res       Date:  2006-12

2.  Serum homocysteine level is increased and correlated with endothelin-1 and nitric oxide in Behçet's disease.

Authors:  H Er; C Evereklioglu; T Cumurcu; Y Türköz; E Ozerol; K Sahin; S Doganay
Journal:  Br J Ophthalmol       Date:  2002-06       Impact factor: 4.638

3.  Interleukin 4, IgG and oligoclonal IgG in aqueous humor of cataract patients.

Authors:  N Stambuk
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1994-09       Impact factor: 3.117

4.  Anti-MHC autoimmunity in Behçet's disease: T cell responses to an HLA-B-derived peptide cross-reactive with retinal-S antigen in patients with uveitis.

Authors:  S Kurhan-Yavuz; H Direskeneli; N Bozkurt; Y Ozyazgan; T Bavbek; H Kazokoglu; E Eksioglu-Demiralp; G Wildner; M Diedrichs-Möhring; T Akoglu
Journal:  Clin Exp Immunol       Date:  2000-04       Impact factor: 4.330

5.  Neurotological status in Behçet's disease and its ophthalmological correlates.

Authors:  Y A Bayazit; C Evereklioğlu; E Ozer; N Kirtak; N Bayazit; M Kanlikama; S Inalöz
Journal:  Postgrad Med J       Date:  2004-12       Impact factor: 2.401

6.  Long-term therapy with low dose cyclosporin A in ocular Behçet's disease.

Authors:  Pinar Cakar Ozdal; Serap Ortaç; Ibrahim Taskintuna; Esin Firat
Journal:  Doc Ophthalmol       Date:  2002-11       Impact factor: 2.379

7.  Interleukin-2 Receptor and Angiotensin-Converting Enzyme as Markers for Ocular Sarcoidosis.

Authors:  Enken Gundlach; Michael Marcus Hoffmann; Antje Prasse; Sonja Heinzelmann; Thomas Ness
Journal:  PLoS One       Date:  2016-01-22       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.